These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 16330442)

  • 41. Response of asymptomatic cytomegalovirus viraemia to oral ganciclovir 3 g/day or 6 g/day in HIV-infected patients.
    Grzywacz M; Deayton JR; Bowen EF; Wilson P; Emery VC; Johnson MA; Griffiths PD
    J Med Virol; 1999 Nov; 59(3):323-8. PubMed ID: 10502264
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Incidence and dynamics of active cytomegalovirus infection in allogeneic stem cell transplant patients according to single nucleotide polymorphisms in donor and recipient CCR5, MCP-1, IL-10, and TLR9 genes.
    Corrales I; Giménez E; Solano C; Amat P; de la Cámara R; Nieto J; Garcia-Noblejas A; Navarro D
    J Med Virol; 2015 Feb; 87(2):248-55. PubMed ID: 25132583
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Risk-adapted pre-emptive therapy for cytomegalovirus disease in patients undergoing allogeneic bone marrow transplantation.
    Mori T; Okamoto S; Matsuoka S; Yajima T; Wakui M; Watanabe R; Ishida A; Iwao Y; Mukai M; Hibi T; Ikeda Y
    Bone Marrow Transplant; 2000 Apr; 25(7):765-9. PubMed ID: 10745263
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Effectiveness of preemptive therapy with ganciclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease].
    Aranda-Verástegui F; Alberú J; Soto-Ramírez LE; González-Aguirre H; Muñoz Trejo T; Mancilla E; Díliz H; Correa-Rotter R; Sierra-Madero J
    Rev Invest Clin; 2002; 54(3):198-203. PubMed ID: 12183888
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cytomegalovirus infection: its incidence and management in cytomegalovirus-seropositive living related liver transplant recipients: a single-center experience.
    Wadhawan M; Gupta S; Goyal N; Vasudevan KR; Makki K; Dawar R; Sardana R; Lal N; Kumar A
    Liver Transpl; 2012 Dec; 18(12):1448-55. PubMed ID: 22903934
    [TBL] [Abstract][Full Text] [Related]  

  • 46. HHV-6-DNAemia related to CMV-DNAemia after liver transplantation.
    Härmä M; Loginov R; Piiparinen H; Halme L; Höckerstedt K; Lautenschlager I
    Transplant Proc; 2005 Mar; 37(2):1230-2. PubMed ID: 15848678
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Rising antigenemia levels may be misleading in pre-emptive therapy of human cytomegalovirus infection in allogeneic hematopoietic stem cell transplant recipients.
    Gerna G; Lilleri D; Zecca M; Alessandrino EP; Baldanti F; Revello MG; Locatelli F
    Haematologica; 2005 Apr; 90(4):526-33. PubMed ID: 15820949
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Use of maintenance therapy and incidence of recurrent Cytomegalovirus DNAemia among allogeneic hematopoietic cell transplant recipients.
    Camargo JF; Anderson AD; Rosa R; Kimble E; Komanduri KV; Morris MI
    Transpl Infect Dis; 2019 Apr; 21(2):e13054. PubMed ID: 30689300
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cytomegalovirus as an etiologic factor in corneal endotheliitis.
    Koizumi N; Suzuki T; Uno T; Chihara H; Shiraishi A; Hara Y; Inatomi T; Sotozono C; Kawasaki S; Yamasaki K; Mochida C; Ohashi Y; Kinoshita S
    Ophthalmology; 2008 Feb; 115(2):292-297.e3. PubMed ID: 17669498
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of cytomegalovirus viremia on subclinical rejection or interstitial fibrosis and tubular atrophy in protocol biopsy at 3 months in renal allograft recipients managed by preemptive therapy or antiviral prophylaxis.
    Reischig T; Jindra P; Hes O; Bouda M; Kormunda S; Treska V
    Transplantation; 2009 Feb; 87(3):436-44. PubMed ID: 19202451
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Active CMV disease does not always correlate with viral load detection.
    Ruell J; Barnes C; Mutton K; Foulkes B; Chang J; Cavet J; Guiver M; Menasce L; Dougal M; Chopra R
    Bone Marrow Transplant; 2007 Jul; 40(1):55-61. PubMed ID: 17468776
    [TBL] [Abstract][Full Text] [Related]  

  • 52. High-dose acyclovir and pre-emptive ganciclovir in prevention of cytomegalovirus disease in pediatric patients following peripheral blood stem cell transplantation.
    Hazar V; Kansoy S; Küpesiz A; Aksoylar S; Kantar M; Yeşilipek A
    Bone Marrow Transplant; 2004 May; 33(9):931-5. PubMed ID: 15034541
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cytomegalovirus infections following chemotherapies of the newer generation.
    Junghanss C
    Haematologica; 2005 Dec; 90(12):1591. PubMed ID: 16330430
    [No Abstract]   [Full Text] [Related]  

  • 54. [Cytomegalovirus diseases after allogeneic hematopoietic stem cell transplantation (Allo-HSCT) and related risk factors].
    Huang XJ; Xu LP; Ren HY; Zhang YC; Guo NL; Lu DP
    Zhonghua Yi Xue Za Zhi; 2003 May; 83(9):766-9. PubMed ID: 12899755
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Leflunomide failure to control recurrent cytomegalovirus infection in the setting of renal failure after allogeneic stem cell transplantation.
    Battiwalla M; Paplham P; Almyroudis NG; McCarthy A; Abdelhalim A; Elefante A; Smith P; Becker J; McCarthy PL; Segal BH
    Transpl Infect Dis; 2007 Mar; 9(1):28-32. PubMed ID: 17313468
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cytomegalovirus antigenemia and outcomes of patients undergoing allogeneic peripheral blood stem cell transplantation: effects of long-term high-dose acyclovir prophylaxis and preemptive ganciclovir treatment.
    Hazar V; Ugur A; Colak D; Saba R; Tezcan G; Kupesiz A; Karadogan I; Gultekin M; Yesilipek A; Undar L
    Jpn J Infect Dis; 2006 Aug; 59(4):216-21. PubMed ID: 16936338
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Increased CMV infection following nonmyeloablative allogeneic stem cell transplantation: a search for the guilty.
    Chakrabarti S
    Blood; 2003 Mar; 101(5):2071. PubMed ID: 12584145
    [No Abstract]   [Full Text] [Related]  

  • 58. Early ganciclovir therapy effectively controls viremia and avoids the need for cytomegalovirus (CMV) prophylaxis in renal transplant patients with cytomegalovirus antigenemia.
    Gotti E; Suter F; Baruzzo S; Perani V; Moioli F; Remuzzi G
    Clin Transplant; 1996 Dec; 10(6 Pt 1):550-5. PubMed ID: 8996777
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cytomegalovirus reactivation following hematopoietic stem cell transplantation.
    Sharma SK; Kumar S; Agrawal N; Singh L; Mukherjee A; Seth T; Mishra P; Mathur S; Dar L; Mahapatra M
    J Infect Dev Ctries; 2013 Dec; 7(12):1003-7. PubMed ID: 24334950
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cytomegalovirus antigenemia and outcome of patients treated with pre-emptive ganciclovir: retrospective analysis of 241 consecutive patients undergoing allogeneic hematopoietic stem cell transplantation.
    Yanada M; Yamamoto K; Emi N; Naoe T; Suzuki R; Taji H; Iida H; Shimokawa T; Kohno A; Mizuta S; Maruyama F; Wakita A; Kitaori K; Yano K; Hamaguchi M; Hamajima N; Morishima Y; Kodera Y; Sao H; Morishita Y
    Bone Marrow Transplant; 2003 Oct; 32(8):801-7. PubMed ID: 14520425
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.